Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.

By H. Eisen, E. Tuzcu, R. Dorent, J. Kobashigawa, D. Mancini, H. A. Valantine-von Kaeppler, R. Starling, K. Sorensen, M. Hummel, Joan Lind and 2 more. New England Journal of Medicine, 2003

1,176 citations recorded by the source corpus.

Subfields: Surgery, Transplantation

View Paper: https://www.semanticscholar.org/paper/e5afdebdcca810cf0cd9378daf2a60732528ba7a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. S. Sánchez
2. A. Demain
3. G. Raimondi
4. A. Thomson
5. H. Turnquist

Citations in the corpus

• Immunoregulatory Functions of mTOR Inhibition (2009, background): “Rapamycin and its derivatives are also undergoing clinical testing for prophylaxis of graft rejectio”
• Microbial drug discovery: 80 years of progress (2009, background): “83 Everolimus is also used in drug-eluting coronary stents as an immunosuppressant to prevent rejection.”